Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$1.80
-10.9%
$2.12
$1.78
$17.31
$49.21MN/A169,145 shs230,165 shs
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$0.20
$0.17
$2.96
$13M-25.92N/AN/A
RenovoRx, Inc. stock logo
RNXT
RenovoRx
$1.35
+3.1%
$1.13
$0.75
$1.69
$47.54M1.3294,619 shs137,545 shs
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$15.67
-1.4%
$19.07
$12.12
$26.99
$49.04M0.5923,270 shs720 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-10.89%-13.46%-11.33%-59.46%+179,999,900.00%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00%0.00%0.00%0.00%-56.53%
RenovoRx, Inc. stock logo
RNXT
RenovoRx
+3.05%+0.75%+14.41%+38.60%+0.75%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-1.42%-7.39%-25.51%-14.21%-25.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
3.0629 of 5 stars
3.50.00.00.03.41.71.3
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/AN/AN/AN/A
RenovoRx, Inc. stock logo
RNXT
RenovoRx
3.0784 of 5 stars
3.55.00.00.03.11.70.0
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
1.5619 of 5 stars
3.53.00.00.01.50.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
3.00
Buy$17.80888.89% Upside
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00
N/AN/AN/A
RenovoRx, Inc. stock logo
RNXT
RenovoRx
3.00
Buy$7.25437.04% Upside
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
3.00
Buy$35.50126.62% Upside

Current Analyst Ratings Breakdown

Latest CHHE, VTVT, ARTV, and RNXT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$12.00
6/5/2025
RenovoRx, Inc. stock logo
RNXT
RenovoRx
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$11.00 ➝ $11.50
5/19/2025
RenovoRx, Inc. stock logo
RNXT
RenovoRx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
5/15/2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$23.00 ➝ $18.00
4/28/2025
RenovoRx, Inc. stock logo
RNXT
RenovoRx
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $11.00
4/9/2025
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$36.00
4/8/2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
4/4/2025
RenovoRx, Inc. stock logo
RNXT
RenovoRx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/27/2025
RenovoRx, Inc. stock logo
RNXT
RenovoRx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$3.00
3/26/2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
3/25/2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$23.00 ➝ $20.00
(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$250K175.41N/AN/A$7.68 per share0.23
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$110K0.00N/A47.17$0.60 per share0.00
RenovoRx, Inc. stock logo
RNXT
RenovoRx
$40K1,234.24N/AN/A$0.19 per share7.11
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$1.02M48.99N/AN/A$4.48 per share3.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$65.37MN/A0.00N/AN/AN/A-75.95%-39.51%6/23/2025 (Estimated)
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
-$410K-$0.020.00N/AN/AN/AN/AN/AN/A
RenovoRx, Inc. stock logo
RNXT
RenovoRx
-$8.81M-$0.40N/AN/AN/AN/A-119.58%-88.01%8/12/2025 (Estimated)
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$18.46M-$3.01N/AN/AN/A-121.46%-46.75%8/6/2025 (Estimated)

Latest CHHE, VTVT, ARTV, and RNXT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
RenovoRx, Inc. stock logo
RNXT
RenovoRx
-$0.08-$0.08N/A-$0.08$0.23 million$0.20 million
5/15/2025Q1 2025
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$0.73-$0.77-$0.04-$0.77N/AN/A
5/8/2025Q1 2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$0.68-$0.83-$0.15-$0.83N/AN/A
3/31/2025Q4 2024
RenovoRx, Inc. stock logo
RNXT
RenovoRx
-$0.12-$0.13-$0.01-$0.12$0.17 million$0.04 million
3/20/2025Q4 2024
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$0.87-$0.55+$0.32-$0.55N/A$0.02 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/AN/AN/AN/AN/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/A
RenovoRx, Inc. stock logo
RNXT
RenovoRx
N/AN/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
13.93
13.93
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/A
RenovoRx, Inc. stock logo
RNXT
RenovoRx
N/A
9.07
9.07
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/A
7.39
7.39

Institutional Ownership

CompanyInstitutional Ownership
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/A
RenovoRx, Inc. stock logo
RNXT
RenovoRx
3.10%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
17.51%

Insider Ownership

CompanyInsider Ownership
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
21.40%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
31.30%
RenovoRx, Inc. stock logo
RNXT
RenovoRx
9.13%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
1.34%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
8124.36 million19.15 millionN/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
4064.95 million44.62 millionNot Optionable
RenovoRx, Inc. stock logo
RNXT
RenovoRx
636.57 million33.23 millionNot Optionable
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
93.19 million3.15 millionNot Optionable

Recent News About These Companies

vTv resumes Phase III oral T1D drug study
vTv Therapeutics initiated with a Buy at H.C. Wainwright
vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year
vTv Therapeutics stock surges on FDA update

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artiva Biotherapeutics stock logo

Artiva Biotherapeutics NASDAQ:ARTV

$1.80 -0.22 (-10.89%)
Closing price 06/17/2025 04:00 PM Eastern
Extended Trading
$1.80 +0.00 (+0.28%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

China Health Industries stock logo

China Health Industries OTCMKTS:CHHE

China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. The company operates through three segments: Humankind, HLJ Huimeijia, and Others. The company offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, hemp frozen age nourishing creams, hemp seed beers, and hemp seeds. It also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, the company offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, it manufactures and sells various types of medical drugs, such as enema glycerini, umguentumacidi borici camphoratum, ge hong beriberi water, pelvic inflammation suppository, injury and paralysis tincture, indometacin and furazolidone suppositories, injury and rheumatism relieving paste, refining goupi cream, muskiness pain relieving paste, muskiness bone strengthener paste, matrine suppositories, ethacriding lactate solution, iodine tincture, mercurochrome solution, hydrogen peroxide solution, halcinonide cream, compound fluocinonide tincture, and policresulen vaginal suppository. The company primarily sells its products through sales personnel and sales agents. China Health Industries Holdings, Inc. was founded in 1996 and is based in Harbin City, the People's Republic of China.

RenovoRx stock logo

RenovoRx NASDAQ:RNXT

$1.35 +0.04 (+3.05%)
Closing price 06/17/2025 04:00 PM Eastern
Extended Trading
$1.35 0.00 (-0.07%)
As of 06/17/2025 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

vTv Therapeutics stock logo

vTv Therapeutics NASDAQ:VTVT

$15.66 -0.23 (-1.42%)
Closing price 06/17/2025 03:58 PM Eastern
Extended Trading
$15.81 +0.15 (+0.93%)
As of 06/17/2025 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.